Longboard announces interim analysis results from OLE Phase 1b/2a PACIFIC study

Longboard Pharmaceuticals announced interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies. “We are thrilled that bexicaserin is continuing to demonstrate a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEE patients. These data provide further support to bexicaserin’s potential to offer a highly differentiated and best-in-class profile,” stated Randall Kaye, Longboard’s Chief Medical Officer. “Given the tremendous unmet need in patients living with DEEs, we are committed to rapidly advancing the development of bexicaserin. We expect to provide a full analysis of participants with 12-month data early next year as they complete the OLE Study and transition to our Expanded Access Program,” Kaye continued. “With Breakthrough Therapy designation granted, we remain on track to initiate our global Phase 3 program for bexicaserin later this year.” The median change in countable motor seizure frequency for participants in the OLE Study over an approximate 9-month treatment period was a decrease of 57.7% from their baseline entering the PACIFIC Study. Continued favorable safety and tolerability results were observed in this study.